Your browser doesn't support javascript.
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
Maillart, Elisabeth; Papeix, Caroline; Lubetzki, Catherine; Roux, Thomas; Pourcher, Valérie; Louapre, Céline.
  • Maillart E; AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France; CRC SEP Paris, France. Electronic address: elisabeth.maillart@aphp.fr.
  • Papeix C; AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France; CRC SEP Paris, France.
  • Lubetzki C; AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France; CRC SEP Paris, France; Sorbonne University, Paris Brain Institute, APHP, Inserm, CNRS, CIC neuroscience, Pitié-Salpêtrière Hospital, Paris, France.
  • Roux T; AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France; CRC SEP Paris, France.
  • Pourcher V; Department of infectious and tropical diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; HIV Pathogenesis and Immune Aging Team, Immunity and Infectious Diseases Research Center, INSERM U1135, Sorbonne University, Paris, France.
  • Louapre C; AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France; CRC SEP Paris, France; Sorbonne University, Paris Brain Institute, APHP, Inserm, CNRS, CIC neuroscience, Pitié-Salpêtrière Hospital, Paris, France.
Mult Scler Relat Disord ; 46: 102482, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-741441
ABSTRACT
Since 2019, a new coronavirus infection (COVID-19) due to an agent called SARS-CoV-2 spread rapidly worldwide. Patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD) are often treated with immunosuppressants. Beyond their effect on the risk of COVID-19 infection, the consequences on the long-term immune response against the coronavirus remain unknown. Among 13 MS or NMOSD patients with confirmed COVID-19 included, all 5 patients treated with anti-CD20 therapies had a negative SARS-CoV-2 serology. To date, maximal precautions to prevent coronavirus infection should be maintained in MS/NMOSD patients already exposed to COVID-19 during anti-CD20 therapy.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuromyelitis Optica / Antigens, CD20 / SARS-CoV-2 / COVID-19 Drug Treatment / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male Language: English Journal: Mult Scler Relat Disord Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuromyelitis Optica / Antigens, CD20 / SARS-CoV-2 / COVID-19 Drug Treatment / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male Language: English Journal: Mult Scler Relat Disord Year: 2020 Document Type: Article